RxDoctor Payments Data

Charles Hollander

Low Vision Rehabilitation · New York, NYNPI 1518950799

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.0% of the total across 88 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by AbbVie at 28.7% of the total. 2025 is the largest year on record at $492, more than ten times the $37 reported in 2019.

$1,920in general payments, 2019–2025

Across 88 payments — averaging $21.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$551
  • Biotissue Holdings Inc.$474
  • Sun Pharmaceutical Industries Inc.$292
  • Alcon$183
  • Coopervision Inc.$146
  • Bausch & Lomb Americas Inc.$138
  • plus $136 from 3 others

What the payments were for

  • Food & beverage$1,90199%
  • Gifts$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,920 in reported general payments places this provider in the 65th percentile of 20 low vision rehabilitation providers in New York.

See all low vision rehabilitation providers in New York

Medicare billing

Part B allowed, 2024
$104,110
Medicare patients
443
Services billed
1,097

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine12$10,875
RhopressaNetarsudil Mesylate11$3,595
Latanoprost52$427
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha25$281
Prednisolone Acetate11$254
Dorzolamide Hcl11$179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$551$10,87512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 20 low vision rehabilitation providers in New York.

Other low vision rehabilitation in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →